ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration

VANCOUVER (British Columbia) and MELBOURNE (Australia) 6th May 2020 – ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement 

Telix is pleased to announce it has entered into a development collaboration agreement with ARTMS Products Inc. (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, to employ ARTMS’ high activity production of Gallium-68 (68Ga) for the manufacture of Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).

To read the full press release please click here.